The management of hydatidiform mole using prophylactic chemotherapy and hysterectomy for high-risk patients decreased the incidence of gestational trophoblastic neoplasia in Vietnam: a retrospective observational study

1. Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol.

2010;203(6):531–539.

2. Sasaki S. Management of gestational trophoblastic diseases in Japan: a review. Placenta. 2003;24(Suppl

A):S28–S32.

3. Kang WD, Choi HS, Kim SM. Prediction of persistent gestational trophoblastic neoplasia: the role of hCG

level and ratio in 2 weeks after evacuation of complete mole. Gynecol Oncol. 2012;124(2):250–253.

4. Kaneki E, Kobayashi H, Hirakawa T, Matsuda T, Kato H, Wake N. Incidence of postmolar gestational tro-

190

Eiko Yamamoto et al

5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. phoblastic disease in androgenetic moles and the morphological features associated with low risk postmolar

gestational trophoblastic disease. Cancer Sci. 2010;101(7):1717–1721.

Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376(9742):717–729.

Horn LC, Kowalzik J, Bilek K, Richter CE, Einenkel J. Clinicopathologic characteristics and subsequent

pregnancy outcome in 139 complete hydatidiform moles. Eur J Obstet Gynecol Reprod Biol. 2006;128(1–

2):10–14.

Golfier F, Raudrant D, Frappart L, et al. First epidemiological data from the French Trophoblastic Disease

Reference Center. Am J Obstet Gynecol. 2007;196(2):172.e1–5.

Berkowitz RS, Goldstein DP. Chorionic tumors. N Engl J Med. 1996;335(23):1740–1748.

Feltmate CM, Growdon WB, Wolfberg AJ, et al. Clinical characteristics of persistent gestational trophoblastic

neoplasia after partial hydatidiform molar pregnancy. J Reprod Med. 2006;51(11):902–906.

Kan M, Yamamoto E, Niimi K, et al. Gestational trophoblastic neoplasia and pregnancy outcome

after routine second curettage for hydatidiform mole: a retrospective observational study. J Reprod Med.

2016;61(7–8):373–379.

Berkowitz RS, Goldstein DP. Clinical practice: molar pregnancy. N Engl J Med. 2009;360(16):1639–1645.

Berkowitz RS, Goldstein DP. Gestational trophoblastic disease. Cancer. 1995;76(10)(Suppl):2079–2085.

Goldstein DP, Berkowitz RS, Bernstein MR. Management of molar pregnancy. J Reprod Med.

1981;26(4):208–212.

Wang Q, Fu J, Hu L, et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational

trophoblastic neoplasia. Cochrane Database Syst Rev. 2017;9:CD007289.

Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C. Epidemiology and aetiology of gestational

trophoblastic diseases. Lancet Oncol. 2003;4(11):670–678.

Bagshawe KD, Dent J, Webb J. Hydatidiform mole in England and Wales 1973–83. Lancet.

1986;2(8508):673–677.

Matsui H, Iitsuka Y, Yamazawa K, Tanaka N, Seki K, Sekiya S. Changes in the incidence of molar

pregnancies: a population-based study in Chiba Prefecture and Japan between 1974 and 2000. Hum Reprod.

2003;18(1):172–175.

Martin BH, Kim JH. Changes in gestational trophoblastic tumors over four decades: a Korean experience.

J Reprod Med. 1998;43(1):60–68.

Song HZ, Wu PC. Hydatidiform mole in China: a preliminary survey of incidence on more than three

million women. Bull World Health Organ. 1987;65(4):507–511.

Sivanesaratnam V. Management of gestational trophoblastic disease in developing countries. Best Pract Res

Clin Obstet Gynaecol. 2003;17(6):925–942.

Tan KC, Karim SM, Ratnam SS. Hydatidiform mole in Singapore. Ann Acad Med Singapore.

1982;11(4):545–548.

Sivanesaratnam V. The management of gestational trophoblastic disease in developing countries such as

Malaysia. Int J Gynaecol Obstet. 1998;60(Suppl 1):S105–S109.

Cagayan MS. Changing trends in the management of gestational trophoblastic diseases in the Philippines.

J Reprod Med. 2010;55(5–6):267–272.

Wairachpanich V, Limpongsanurak S, Lertkhachonsuk R. Epidemiology of hydatidiform moles in a tertiary

hospital in Thailand over two decades: impact of the national health policy. Asian Pac J Cancer Prev.

2015;16(18):8321–8325.

Lao TT, Lee FH, Yeung SS. Repeat curettage after evacuation of hydatidiform mole: an appraisal. Acta

Obstet Gynecol Scand. 1987;66(4):305–307.

Zhao P, Lu Y, Huang W, Tong B, Lu W. Total hysterectomy versus uterine evacuation for preventing

post-molar gestational trophoblastic neoplasia in patients who are at least 40 years old: a systematic review

and meta-analysis. BMC Cancer. 2019;19(1):13.

Cuong DT. Gestational trophoblastic disease in Vietnam prevalence, clinical features, management. Int J

Gynaecol Obstet. 1998;60(Suppl 1):S131.

Maestá I, Nitecki R, Horowitz NS, et al. Effectiveness and toxicity of first-line methotrexate chemotherapy

in low-risk postmolar gestational trophoblastic neoplasia: the New England Trophoblastic Disease Center

experience. Gynecol Oncol. 2018;148(1):161–167.

Kohorn EI. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease:

description and critical assessment. Int J Gynecol Cancer. 2001;11(1):73–77.

Thi Thao Nguyen S, Yamamoto E, Thi Ngoc Nguyen M, et al. Waiting time in the outpatient clinic at a

national hospital in Vietnam. Nagoya J Med Sci. 2018;80(2):227–239.

Tien Dat T, Kotani T, Yamamoto E, et al. Dengue fever during pregnancy. Nagoya J Med Sci.

191

Hydatidiform mole in Vietnam

2018;80(2):241–247.

32. Yamamoto E, Niimi K, Fujikake K, et al. High-dose chemotherapy with autologous peripheral blood

stem cell transplantation for choriocarcinoma: a case report and literature review. Mol Clin Oncol.

2016;5(5):660–664.

33. Lewis J, Jr., Gore H, Hertig AT, Goss DA. Treatment of trophoblastic disease: with rationale for the use

of adjunctive chemotherapy at the time of indicated operation. Am J Obstet Gynecol. 1966;96(5):710–722.

34. Kim DS, Moon H, Kim KT, Moon YJ, Hwang YY. Effects of prophylactic chemotherapy for persistent

trophoblastic disease in patients with complete hydatidiform mole. Obstet Gynecol. 1986;67(5):690–694.

35. Fasoli M, Ratti E, Franceschi S, La Vecchia C, Pecorelli S, Mangioni C. Management of gestational

trophoblastic disease: results of a cooperative study. Obstet Gynecol. 1982;60(2):205–209.

36. Park TK, Kim SN, Lee SK. Analysis of risk factors for postmolar trophoblastic disease: categorization of

risk factors and effect of prophylactic chemotherapy. Yonsei Med J. 1996;37(6):412–419.

37. Limpongsanurak S. Prophylactic actinomycin D for high-risk complete hydatidiform mole. J Reprod Med.

2001;46(2):110–116.

38. Kashimura Y, Kashimura M, Sugimori H, et al. Prophylactic chemotherapy for hydatidiform mole: five to

15 years follow-up. Cancer. 1986;58(3):624–629.

39. Ratnam SS, Teoh ES, Dawood MY. Methotrexate for prophylaxis of choriocarcinoma. Am J Obstet Gynecol.

1971;111(8):1021–1027.

40. Zhao P, Chen Q, Lu W. Comparison of different therapeutic strategies for complete hydatidiform mole in

women at least 40 years old: a retrospective cohort study. BMC Cancer. 2017;17(1):733.

41. Uberti EM, Fajardo Mdo C, da Cunha AG, et al. Prevention of postmolar gestational trophoblastic neoplasia

using prophylactic single bolus dose of actinomycin D in high-risk hydatidiform mole: a simple, effective,

secure and low-cost approach without adverse effects on compliance to general follow-up or subsequent

treatment. Gynecol Oncol. 2009;114(2):299–305.

42. Lawrie TA, Alazzam M, Tidy J, Hancock BW, Osborne R. First-line chemotherapy in low-risk gestational

trophoblastic neoplasia. Cochrane Database Syst Rev. 2016(6):CD007102.

43. Seckl MJ, Sebire NJ, Fisher RA, et al. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines

for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi39–50.

...